A Bio research company with these financials but trading this low! How sad
$Nektar Therapeutics(NKTR.US$ • Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata.
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75 million to $85 million.
• The company has no debt and anticipates year-end cash and investments for 2024 to be between $200 million and $225 million.
• R&D expenses for 2024 are estimated to be between $120 million and $130 million.
Company Outlook
• Nektar Therapeutics projects a cash runway extension due to a $30 million financing.
• They forecast revenues between $75 million and $85 million for 2024 and year-end cash and investments in the range of $200 million to $225 million.
Bearish Highlights
• The company faces challenges in developing treatments for conditions with high variability, such as alopecia areata.
Bullish Highlights
• Positive impressions from doctors on the rapid onset and durability of the response in clinical trials for atopic dermatitis.
• The unique signaling properties of the NKTR-0165 antibody could differentiate it in the treatment of autoimmune diseases
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75 million to $85 million.
• The company has no debt and anticipates year-end cash and investments for 2024 to be between $200 million and $225 million.
• R&D expenses for 2024 are estimated to be between $120 million and $130 million.
Company Outlook
• Nektar Therapeutics projects a cash runway extension due to a $30 million financing.
• They forecast revenues between $75 million and $85 million for 2024 and year-end cash and investments in the range of $200 million to $225 million.
Bearish Highlights
• The company faces challenges in developing treatments for conditions with high variability, such as alopecia areata.
Bullish Highlights
• Positive impressions from doctors on the rapid onset and durability of the response in clinical trials for atopic dermatitis.
• The unique signaling properties of the NKTR-0165 antibody could differentiate it in the treatment of autoimmune diseases
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
